Illumina’s first quarter reflected consistent execution across its clinical and instrument businesses. Management highlighted strong demand in clinical sequencing, which now represents more than 65% of sequencing consumables revenue, and robust uptake of the NovaSeq X platform, with over 80 placements in the quarter. CEO Jacob Thaysen credited disciplined operational performance and expansion of sequencing-based diagnostics for driving revenue and margin growth, noting, “Our focus on delivering for our customers and shareholders is fueling the sustained success that positions us for continued growth well into the future.”
Is now the time to buy ILMN? Find out in our full research report (it’s free for active Edge members).
Illumina (ILMN) Q1 CY2026 Highlights:
- Revenue: $1.09 billion vs analyst estimates of $1.07 billion (4.8% year-on-year growth, 1.8% beat)
- Adjusted EPS: $1.15 vs analyst estimates of $1.05 (9% beat)
- Adjusted EBITDA: $299.7 million vs analyst estimates of $295.8 million (27.5% margin, 1.3% beat)
- The company slightly lifted its revenue guidance for the full year to $4.57 billion at the midpoint from $4.55 billion
- Management raised its full-year Adjusted EPS guidance to $5.23 at the midpoint, a 2% increase
- Operating Margin: 19.2%, up from 15.8% in the same quarter last year
- Organic Revenue rose 1.2% year on year (beat)
- Market Capitalization: $21.57 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Illumina’s Q1 Earnings Call
- Vijay Kumar (Evercore ISI) asked about the relatively modest increase in organic revenue guidance despite strong clinical momentum. CEO Jacob Thaysen said the company remains optimistic but is “only one quarter into the year,” balancing early outperformance with prudent forecasting.
- Puneet Souda (Leerink) inquired about the mix of NovaSeq X placements between clinical and research, and the impact of pricing transitions. Thaysen clarified that over 60% of placements were in clinical, driving incremental revenue, with pricing assumptions already incorporated into guidance.
- Tycho Peterson (Jefferies) questioned the risk of market “freezing” as Illumina rolls out new roadmaps. Thaysen stated, “our placements of instruments show that there is no freezing,” and emphasized robust demand and an 18-month innovation roadmap.
- Madeline (Wolfe Research) asked about operating margin progression given Q2 headwinds. CFO Ankur Dhingra responded that investments and inflation would impact early quarters, but margin improvement is expected in the second half as mitigation efforts take hold.
- Patrick Donnelly (Citi) sought clarity on trends in research and applied markets. Thaysen said funding remains cautious, with any improvement considered an upside not yet built into the outlook.
Catalysts in Upcoming Quarters
In upcoming quarters, the StockStory team will watch (1) whether clinical sequencing maintains its double-digit growth pace as new NovaSeq X instruments are installed, (2) successful launch and adoption of spatial transcriptomics and advanced flow cells, and (3) signs of stabilization or recovery in research and applied markets as funding dynamics evolve. Additionally, ongoing integration of SomaLogic and the ability to offset inflationary pressures will be key performance indicators.
Illumina currently trades at $142, up from $126.74 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
